ISTA Pharmaceuticals, Inc.

The US Food and Drug Administration rarely issues a public announcement offering a sponsor the chance to request a hearing to defend a new drug application it plans to reject. But the agency now may h

Valeant Pharmaceuticals' CEO J Michael Pearson was in Asia when the news broke at the start of this week that Valeant had lost out to Actavis in its bid for Allergan. As a result, "We haven't had time

Even as the scandal involving the Internal Revenue Service threatens to derail any congressional efforts this year for a comprehensive tax code overhaul, a newly formed coalition of small businesses h

Lawyers predict that FDA’s proposed rule to enable generic manufacturers to unilaterally change their labeling to include new safety information will give the plaintiffs bar a weapon to pursue new cla